Role of Trimetazidine in Coronary Artery Bypass Graft Surgery  

作　　者：Gerez Fernandes Martins Gerez Martins 

机构地区：[1]Cardiac Surgery Department, Institute of Cardiology State Aloysio de Castro, Rio de Janeiro, Brazil [2]Cardiology Department, Institute of Cardiology State Aloysio de Castro, Rio de Janeiro, Brazil

出　　处：《World Journal of Cardiovascular Surgery》2017年第7期87-102,共16页心血管外科国际期刊（英文）

摘　　要：Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. The aim of this review is to objectively evaluate the effects of the drug trimetazidine (TMZ) on ischemia-reperfusion injury in coronary artery bypass graft surgery by reviewing all known studies from recent years.Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on segments of cellular metabolism, used in isolation or combined to reduce or prevent damage to the cardiac cell. The aim of this review is to objectively evaluate the effects of the drug trimetazidine (TMZ) on ischemia-reperfusion injury in coronary artery bypass graft surgery by reviewing all known studies from recent years.

关 键 词：ISCHEMIA-REPERFUSION Injury Oxidative Stress Inflammation TRIMETAZIDINE CORONARY ARTERY BYPASS GRAFT 

分 类 号：R54[医药卫生—心血管疾病]